High dose oral furosemide with salt ingestion in the treatment of refractory ascites of liver cirrhosis
dc.authorscopusid | 24470317500 | |
dc.authorscopusid | 58602450200 | |
dc.authorscopusid | 56478465500 | |
dc.authorscopusid | 25641781500 | |
dc.authorscopusid | 35796175800 | |
dc.authorscopusid | 7004054394 | |
dc.contributor.author | Yakar, Tolga | |
dc.contributor.author | Demir, Mehmet | |
dc.contributor.author | Dogan, Ozlem | |
dc.contributor.author | Parlakgumus, Alper | |
dc.contributor.author | Ozer, Birol | |
dc.contributor.author | Serin, Ender | |
dc.date.accessioned | 2024-09-19T15:49:53Z | |
dc.date.available | 2024-09-19T15:49:53Z | |
dc.date.issued | 2016 | |
dc.department | Hatay Mustafa Kemal Üniversitesi | en_US |
dc.description.abstract | Purpose: We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+ furosemide (i.v.) and repeated paracentesis in patients with RA. Methods: This was a prospective study of 78 cirrhotic patients with RA, randomized into three groups: Group A (n= 25) i.v. furosemide (200-300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day); Group B (n= 26) oral furosemide tablets (360-520 mg bid) and salt (2.5 g bid); and, Group C (n= 27) repeated large-volume-paracentesis (RLVP) with albumin infusion. Patients without hyperkalemia were administrated 100 mg of spironolactone/day. During the follow-up; INR, creatinine, and total bilirubin levels were measured to determine the change in MELD (model of end stage liver disease) score. Results: Hepatic encephalopathy (HE), severe episodes of spontaneous bacterial peritonitis (SBP) and pleural effusions (PE) occurred more frequently in Group C. Improvement in Child-Pugh and MELD score was better in Group A and B than Group C. In Group B, improvements were seen in the Child-Pugh and MELD score, reduction in body weight, duration and number of hospitalization. In Groups A and B, remarkable increases in diuresis were observed (706±116 to 2425±633 mL and 691±111 to 2405±772 mL) and serum sodium levels also improved. HE and SBP were occurred more often in group C (p<0.002). Hospitalization decreased significantly in Group B (p<0.001). There was no significant difference in survival among groups. Conclusion: High dose oral furosemide with salt ingestion may be an alternative, effective, safe and well-tolerated method of therapy for RA. © 2016 CIM. | en_US |
dc.identifier.endpage | S60 | en_US |
dc.identifier.issn | 0147-958X | |
dc.identifier.issue | 6 | en_US |
dc.identifier.pmid | 27917793 | en_US |
dc.identifier.scopus | 2-s2.0-85009996946 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | S52 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12483/15473 | |
dc.identifier.volume | 39 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | The Canadian Society for Clinical Investigation | en_US |
dc.relation.ispartof | Clinical and Investigative Medicine | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | High dose oral furosemide with salt ingestion in the treatment of refractory ascites of liver cirrhosis | en_US |
dc.type | Article | en_US |